文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

社区获得性肺炎且呼吸道病毒检测阳性患者中抗生素使用与结局的关联

Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该回顾性多中心研究纳入6779例疑似社区获得性肺炎且呼吸道病毒检测阳性的住院患者,比较0-2天与5-7天抗生素治疗,经倾向加权后两组在住院时长、ICU入住、死亡等结局无显著差异,提示多数此类患者抗生素无获益。

要点

  • 病毒阳性CAP住院患者抗生素使用时长差异大,但0-2天与5-7天结局相似
  • 缩短抗生素疗程未增加住院时长、ICU入住或死亡风险
  • 结果在非SARS-CoV-2病毒和流感亚组中一致

核心结论

  • 疑似CAP且呼吸道病毒检测阳性的住院患者中,0-2天与5-7天抗生素治疗的结局无显著差异,提示多数患者抗生素无获益。

研究设计与样本

  • 采用倾向加权比较抗生素治疗0-2天与5-7天患者的结局,加权后分析2614例(0-2天组1720例,5-7天组894例)。

主要发现

  • 加权后两组住院时长11.7天 vs 11.1天(OR 1.05,95%CI 0.97-1.15),无显著差异。
  • 限制于非SARS-CoV-2病毒、流感单独分析、0天 vs 5-7天比较及入院时ICD-10肺炎编码患者时结果一致。

临床怎么用

  • 对于疑似CAP且呼吸道病毒检测阳性的住院患者,可考虑缩短抗生素疗程至0-2天,而不增加不良结局风险。
  • 临床决策应结合个体情况,避免对所有病毒阳性CAP患者常规使用5-7天抗生素。

局限性

  • 回顾性研究设计可能存在未测量混杂。
  • 倾向加权仅纳入部分患者,可能存在选择偏倚。
  • 结果主要适用于类似医疗环境,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Newly released community-acquired pneumonia (CAP) guidelines include a conditional recommendation to treat all hospitalized patients with positive respiratory virus assays with antibacterials. We assessed the frequency, duration, and outcomes of antibacterial prescribing in this population. METHODS: We retrospectively identified all hospitalized patients with possible CAP and a positive respiratory virus test at 5 hospitals, June 2015-December 2024. We used detailed clinical data to propensity-weight patients treated with 0-2 versus 5-7 days of antibacterials and compared outcomes overall and for different viruses. RESULTS: Among 6779 patients with possible CAP and a respiratory virus, 3269 were treated with 0-2 days and 1560 with 5-7 days of antibacterials. After propensity-weighting 2614 patients (1720 treated 0-2 days, 894 treated 5-7 days), there were no significant differences in hospital length of stay (11.7 days vs 11.1 days; OR 1.05, 95% CI .97-1.15), ICU admission after 48 hours (28.3% vs 28.2%; OR 1.01, 95% CI .86-1.18), in-hospital mortality (9.5% vs 9.8%; OR 0.97, 95% CI .74-1.27), or 30-day hospital-free days (16.9 days vs 17.0 days; OR 0.99, 95% CI .95-1.03). Results were consistent when restricted to non-SARS-CoV-2 viruses and to influenza alone, when comparing 0 versus 5-7 days of antibacterials, and when restricting to patients with ICD-10 codes for pneumonia present on admission. CONCLUSIONS: Antibacterial use for patients with possible CAP and respiratory viruses is highly variable but outcomes are similar with 0-2 versus 5-7 days of antibacterials. This suggests antibiotics are not beneficial in most CAP patients who test positive for respiratory viruses.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Biebelberg B, Chen T, McKenna C, et al. Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays. Clin Infect Dis. 2026. PMID: 41378862. doi:10.1093/cid/ciaf687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。